Medicare Rx Formularies Need Independent "Watchdog," Consumers Union Says
This article was originally published in The Pink Sheet Daily
Executive Summary
An independent group of medical experts would protect beneficiaries from the conflicting interests of pharmaceutical manufacturers and payors, Consumers Union tells the U.S. Pharmacopeia public meeting on Medicare formulary guidelines.
You may also be interested in...
CMS Medicare Formulary Standards Will Have More “Granularity” Than USP
The Centers for Medicare & Medicaid Services expects its reviews of Medicare Rx drug plan formularies to include evaluation of drug choices at the “sub-class” level. The standards will also aim to encourage plans to provide more than the minimum two drugs per formulary class.
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability